MARKET

ALBO

ALBO

Albireo Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.31
-0.07
-0.24%
After Hours: 29.55 +0.24 +0.82% 19:10 07/29 EDT
OPEN
29.57
PREV CLOSE
29.38
HIGH
30.25
LOW
28.60
VOLUME
208.55K
TURNOVER
--
52 WEEK HIGH
49.00
52 WEEK LOW
22.78
MARKET CAP
562.60M
P/E (TTM)
-4.2376
1D
5D
1M
3M
1Y
5Y
Albireo to Report Second Quarter 2021 Financial Results on August 5
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on August 5, 2021, to provide a business update and...
GlobeNewswire · 18h ago
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.
Benzinga · 4d ago
Baird Adjusts Albireo Pharma's Price Target to $72 From $67, Keeps Outperform Rating
MT Newswires · 07/22 10:09
Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug
Zacks.com · 07/21 14:51
Wedbush Maintains Outperform on Albireo Pharma, Raises Price Target to $82
Wedbush analyst Liana Moussatos maintains Albireo Pharma (NASDAQ:ALBO) with a Outperform and raises the price target from $73 to $82.
Benzinga · 07/21 12:41
HC Wainwright & Co. Maintains Buy on Albireo Pharma, Raises Price Target to $79
HC Wainwright & Co. analyst Ed Arce maintains Albireo Pharma (NASDAQ:ALBO) with a Buy and raises the price target from $76 to $79.
Benzinga · 07/21 10:19
Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US
Benzinga · 07/21 10:10
HC Wainwright Adjusts Albireo Pharma's Price Target to $79 From $76, Keeps Buy Rating
MT Newswires · 07/21 07:28
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALBO. Analyze the recent business situations of Albireo Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALBO stock price target is 75.86 with a high estimate of 82.00 and a low estimate of 68.00.
EPS
Institutional Holdings
Institutions: 141
Institutional Holdings: 19.74M
% Owned: 102.85%
Shares Outstanding: 19.19M
TypeInstitutionsShares
Increased
40
1.08M
New
7
82.12K
Decreased
35
907.24K
Sold Out
12
197.46K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Independent Director
David Chiswell
President/Chief Executive Officer/Director
Ronald Cooper
Chief Financial Officer/Treasurer
Simon Harford
Chief Human Resource Officer
Michelle Graham
Chief Scientific Officer
Jan Mattsson
General Counsel/Secretary
Jason Duncan
Other
Martha Carter
Other
Patrick Horn
Other
Pamela Stephenson
Independent Director
Michael Gutch
Independent Director
Roger Jeffs
Independent Director
Anne Klibanski
Independent Director
Stephanie Okey
Independent Director
Davey Scoon
No Data
About ALBO
Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).

Webull offers kinds of Albireo Pharma Inc stock information, including NASDAQ:ALBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALBO stock methods without spending real money on the virtual paper trading platform.